Dr. Laura Valtere
speaker
54 appearances
1 recordings
1 series
first heard Jul 2026
last heard 8 Jul
Dr. Laura Valtere’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.
Appearances
Unpacking AMR · New Conceptions to Manage AMR – Part 4 – Collective Action Problems · 8 Jul 2026
podcast
That we really need to address both bacteria
In in instances where countries are unable to act, for example due to limited infrastructure or weak regulation or insufficient funding, these regions can unintentionally become hotspots for the emergence and proliferation of resistant pathogens.
As these pathogens do not respect national borders, these failures have a detrimental effect on the global effort to preserve antibiotic efficacy.
And and we can ask what is the structural impact in in this regard.
The inability to act is not uh not just a local tragedy but what is tra ch strategical uh structural threat to to global community.
Even if um high income nations are rigorous in their stewardship, their populations are still vulnerable to resistant organisms imported imported from regions lacking the necessary information.
Yeah, Daniel mentioned probably the two of the most imp important uh aspects, infrastructure and institutional structures, but as well, of course, this is about resources.
And um high income countries uh probably possess much more uh resources to to achieve goals uh uh more efficiently.
Uh but then there are also
Beyond the technical gaps, there are there are also often fundamental mismatches between the idealized stewardship model and the reality on the ground.
This we especially see in our international meetings with colleagues uh from abroad the world.
The stewardship that it it can be confusing or even culturally irrelevant in some regions because there are other competing health priorities such as acute infection disease outbreaks or malnutrition.
Um that uh yeah that that that are the major
From the from the global perspective or global view the I think that the domestic uh focus strategy
fails to acknowledge the global nature of the AMR issue, which is a shared resource problem basically.
The ability of pathogens we know they they evolve and spread across borders and that makes national only policies ineffective.
To give an example, focusing on on on national incentives for new antibiotic development without addressing the global access and excess crisis can lead actually to market failures.
If new drugs are not accessible accessible uh to the rest of the world, resistance will inevitably arise in these markets and eventually circulate back to to nations that can afford new expensive treatments, basically nullifying the initial investment.
And that's why also we know that we have in Europe um legislative developments uh uh providing various uh innovation incentives, uh but uh regional uh regional tools to to to of course there will be spillovers also also useful for for the global community, but if there will not be uh equitable access uh tools uh for other regions, these innovative treaties.
treatment um the consequences uh will not be that uh prosperous and virtuous.
Showing 1–20 of 54 · page 1 of 3
Next →